Pilitsi, Eleni; Farr, Olivia M.; Polyzos, Stergios A.; Perakakis, Nikolaos; Nolen-Doerr, Eric; Papathanasiou, Aimilia-Eirini; Mantzoros, Christos S. published the artcile< Pharmacotherapy of obesity: Available medications and drugs under investigation>, COA of Formula: C29H53NO5, the main research area is adult obesity pharmacol management FDA approved medication drug review; Liraglutide; Lorcaserin; Naltrexone/bupropion; Obesity; Orlistat; Personalized therapy phentermine/topiramate.
A review. Obesity is a chronic disease with a continuously rising prevalence that currently affects more than half a billion people worldwide. Energy balance and appetite are highly regulated via central and peripheral mechanisms, and weight loss triggers a homeostatic response leading to weight regain. Lifestyle and behavioral modifications are the cornerstones of obesity management; however, they often fail to achieve or sustain long-term weight loss. Pharmacotherapy added onto lifestyle modifications results in an addnl., albeit limited, weight reduction Regardless, this weight reduction of 5-10% conveys multiple cardiovascular and metabolic benefits. In this review, evidence on the food and drug administration (FDA)-approved medications, i.e., orlistat, lorcaserin, phentermine/topiramate, liraglutide and naltrexone/bupropion, is summarized. Furthermore, anti-obesity agents in the pipeline for potential future therapeutic use are presented.
Metabolism, Clinical and Experimental published new progress about Pipelines. 96829-58-2 belongs to class amides-buliding-blocks, and the molecular formula is C29H53NO5, COA of Formula: C29H53NO5.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics